60.09

1.71% -1.16

Verona Pharma Plc Adr (VRNA)

Overview News Price History Option Chain Financials Discussions Forecast

Verona Pharma Plc Adr stock is traded at $60.09, with a volume of 549.78K. It is down -1.71% in the last 24 hours and up +21.50% over the past month. Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

Previous Close:

$61.25

Open:

$61

24h Volume:

549.78K

Relative Volume:

0.46

Market Cap:

$5.01B

Revenue:

Net Income/Loss:

$-153.72M

P/E Ratio:

-30.05

EPS:

-2

Net Cash Flow:

$-103.81M

1W Performance:

+5.06%

1M Performance:

+21.50%

6M Performance:

+208.25%

1Y Performance:

+268.43%

1-Day Range:

$59.82

$61.43

1-Week Range:

$55.42

$62.00

52-Week Range:

$11.39

$62.00

Verona Pharma Plc Adr Stock (VRNA) Company Profile

Name

Verona Pharma Plc Adr

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

011-44-0-2032834200

Address

3 MORE LONDON RIVERSIDE, LONDON

Employee

Twitter

@VeronaPharma

Next Earnings Date

2024-11-04

Latest SEC Filings

VRNA's Discussions on Twitter

Compare VRNA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VRNA Verona Pharma Plc Adr	60.22	5.01B	0	-153.72M	-103.81M	-2.00
VRTX Vertex Pharmaceuticals Inc	473.55	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	716.08	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	653.00	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	274.85	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.70	28.75B	3.30B	-501.07M	1.03B	-2.1146

Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-10-25	Initiated	ROTH MKM	Buy
Oct-03-24	Initiated	Wells Fargo	Overweight
May-22-23	Resumed	Jefferies	Buy
Sep-19-22	Resumed	Wedbush	Outperform
Aug-26-22	Initiated	Piper Sandler	Overweight
Sep-13-21	Initiated	H.C. Wainwright	Buy
Aug-25-20	Initiated	Jefferies	Buy
Aug-10-20	Initiated	Canaccord Genuity	Buy
Apr-18-19	Initiated	BTIG Research	Buy

View All

Verona Pharma Plc Adr Stock (VRNA) Latest News

Feb 06, 2025

Are Smart Investors Making the Right Decision? Verona Pharma Plc ADR (VRNA) - SETE News

Feb 06, 2025

Healthy Upside Potential: Solidion Technology Inc (STI) - SETE News

Feb 06, 2025

Feb 05, 2025

Stock Surge: XPO Inc (XPO) Closes at 131.50, Marking a 2.24 Increase/Decrease - The Dwinnex

Feb 05, 2025

Closing Figures Unveiled: Diageo plc ADR (DEO) Drop -0.84, Closes at 115.95 - The Dwinnex

Feb 05, 2025

Market Watch Highlights: Verona Pharma Plc ADR (VRNA) Ends on an Upturn Note at 59.94 - The Dwinnex

Feb 05, 2025

Market Momentum Report: Lemonade Inc (LMND)’s Positive Close at 33.99 - The Dwinnex

Feb 05, 2025

Checking in on Verona Pharma Plc ADR (VRNA) after recent insiders movement - Knox Daily

Feb 04, 2025

A closer look at Centessa Pharmaceuticals plc ADR (CNTA) is warranted - US Post News

Feb 04, 2025

Have you been able to find a good deal on Verona Pharma Plc ADR’s shares? - US Post News

Feb 04, 2025

The Agilon Health Inc (AGL) had a good session last reading, didn’t it? - US Post News

Feb 04, 2025

How should investors view Relay Therapeutics Inc (RLAY)? - US Post News

Feb 04, 2025

Jan 21, 2025

Bronchiectasis Market to Show Positive Growth at a CAGR of 13.7% by 2034 | DelveInsight - GlobeNewswire Inc.

Jan 21, 2025

Verona Pharma stock target upgraded, retains buy on Q4 results By Investing.com - Investing.com South Africa

Jan 21, 2025

Jan 17, 2025

Looking For A Top Momentum Pick? Why Valley National Bancorp (NASDAQ: VLY) Is A Great Choice - Stocks Register

Jan 17, 2025

Hertz Global Holdings Inc (NASDAQ: HTZ): Overvalued Compared To Others? - Stocks Register

Jan 17, 2025